ICYMI: May 7, 2015
PharmaExec.com: “Take a Breath” on the Specialty Drug Pricing Issue…?
“The global market for cancer drugs has hit $100 billion in annual sales, and could reach $147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics, a unit of drug data provider IMS Health.”
“Here are more stats for the price-increase tally: Twenty-seven drug brands took 20% price increases last year, and dozens saw prices at least double over the past 5 years, Bloomberg reports. Once again, the usual suspects top the price-increase lists. And diabetes products are conspicuously present.
With a 351% increase, Jazz Pharmaceuticals’ ($JAZZ) narcolepsy drug Xyrem came in first place for 5-year hikes. Welchol, the Daiichi Sankyo cholesterol med, topped the list of last year’s hikes with a 40.3% increase. Mylan’s ($MYL) EpiPen came in close behind with a 32% increase.”